UY34632A - Compuestos de oxazolidin- 2- ona y usos de los mismos - Google Patents
Compuestos de oxazolidin- 2- ona y usos de los mismosInfo
- Publication number
- UY34632A UY34632A UY0001034632A UY34632A UY34632A UY 34632 A UY34632 A UY 34632A UY 0001034632 A UY0001034632 A UY 0001034632A UY 34632 A UY34632 A UY 34632A UY 34632 A UY34632 A UY 34632A
- Authority
- UY
- Uruguay
- Prior art keywords
- oxazolidin
- same
- ona
- compounds
- ona compounds
- Prior art date
Links
- FWYUJENICVGSJH-UHFFFAOYSA-M sodium;2-[bis[2-[2-(2-methyl-5-nitroimidazol-1-yl)ethoxy]-2-oxoethyl]amino]acetate Chemical compound [Na+].CC1=NC=C([N+]([O-])=O)N1CCOC(=O)CN(CC([O-])=O)CC(=O)OCCN1C([N+]([O-])=O)=CN=C1C FWYUJENICVGSJH-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261602954P | 2012-02-24 | 2012-02-24 | |
| US201261736707P | 2012-12-13 | 2012-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY34632A true UY34632A (es) | 2013-05-31 |
Family
ID=48142031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001034632A UY34632A (es) | 2012-02-24 | 2013-02-21 | Compuestos de oxazolidin- 2- ona y usos de los mismos |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8865894B2 (https=) |
| EP (1) | EP2817307B1 (https=) |
| JP (1) | JP6154404B2 (https=) |
| KR (1) | KR101640698B1 (https=) |
| CN (1) | CN104144926B (https=) |
| AP (1) | AP2014007835A0 (https=) |
| AR (1) | AR090121A1 (https=) |
| AU (1) | AU2013223713C1 (https=) |
| BR (1) | BR112014020672B1 (https=) |
| CA (1) | CA2865372A1 (https=) |
| CO (1) | CO7051028A2 (https=) |
| CR (1) | CR20140397A (https=) |
| DO (1) | DOP2014000194A (https=) |
| EA (1) | EA026031B1 (https=) |
| ES (1) | ES2598118T3 (https=) |
| GE (1) | GEP20156389B (https=) |
| GT (1) | GT201400178A (https=) |
| HK (1) | HK1199643A1 (https=) |
| IL (1) | IL233936A (https=) |
| MX (1) | MX353341B (https=) |
| NI (1) | NI201400089A (https=) |
| NZ (1) | NZ629198A (https=) |
| PE (1) | PE20142456A1 (https=) |
| PH (1) | PH12014501900A1 (https=) |
| PL (1) | PL2817307T3 (https=) |
| PT (1) | PT2817307T (https=) |
| SG (1) | SG11201404794XA (https=) |
| TW (1) | TW201339155A (https=) |
| UY (1) | UY34632A (https=) |
| WO (1) | WO2013124826A1 (https=) |
| ZA (1) | ZA201405446B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014007310A2 (pt) | 2011-09-27 | 2017-04-04 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| JP6404217B2 (ja) * | 2012-09-11 | 2018-10-10 | メディベイション プロステイト セラピューティクス エルエルシー | エンザルタミドの製剤 |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| JP6387360B2 (ja) | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| MX373444B (es) | 2014-03-24 | 2020-04-30 | Novartis Ag | Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas. |
| TW201609108A (zh) | 2014-07-25 | 2016-03-16 | 諾華公司 | 醫藥劑型 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| ES2807785T3 (es) | 2014-10-22 | 2021-02-24 | Bristol Myers Squibb Co | Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k |
| EP3209665B1 (en) | 2014-10-22 | 2019-08-14 | Bristol-Myers Squibb Company | Substituted pyrrolotriazine amine compounds as pi3k inhibitors |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| EA035817B1 (ru) | 2015-03-10 | 2020-08-14 | Адуро Байотек, Инк. | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" |
| AU2016287463B2 (en) * | 2015-07-02 | 2020-07-02 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
| CN111848643A (zh) * | 2015-07-02 | 2020-10-30 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| PE20181326A1 (es) | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| EA201991069A1 (ru) * | 2016-11-02 | 2019-10-31 | Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом | |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| MY204117A (en) | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| US11919902B2 (en) | 2017-12-22 | 2024-03-05 | Hibercell, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CN109134558A (zh) * | 2018-09-21 | 2019-01-04 | 常州方圆制药有限公司 | 一种提高1-N-乙基庆大霉素Cla收率的合成方法 |
| CN109970764B (zh) * | 2019-03-26 | 2021-11-09 | 上海吉奉生物科技有限公司 | 一种（S）-1,1,5,5-四甲基二氢恶唑并[3,4-c]恶唑-3-酮的合成方法 |
| CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
Family Cites Families (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB581334A (en) | 1943-09-29 | 1946-10-09 | Francis Henry Swinden Curd | New pyrimidine compounds |
| JPS4921148Y1 (https=) | 1970-02-07 | 1974-06-06 | ||
| JPS4921149Y1 (https=) | 1970-06-27 | 1974-06-06 | ||
| JPS4921148B1 (https=) | 1970-12-28 | 1974-05-30 | ||
| JPS4921149B1 (https=) | 1970-12-28 | 1974-05-30 | ||
| DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| AT340933B (de) | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US4994386A (en) | 1987-07-13 | 1991-02-19 | Pharmacia Diagnostics, Inc. | Production of HBLV virus in the HSB-2 cell line |
| US4929726A (en) | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
| EP0330263A1 (en) | 1988-02-25 | 1989-08-30 | Merck & Co. Inc. | Piperazinylalkylpyrimidines as hypoglycemic agents |
| GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| CA2065443A1 (en) | 1990-07-03 | 1992-01-04 | Akira Mizuchi | Pyrimidine compound and pharmaceutically acceptable salts thereof |
| KR100275300B1 (ko) | 1995-04-13 | 2000-12-15 | 고바야시 유키오 | 신규 4,6-디아릴피리미딘 유도체 및 그 염(novel 4,6-diarylpyrimidine derivatives and salts thereof) |
| JP3734907B2 (ja) | 1996-12-19 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
| CN1129597C (zh) | 1997-07-24 | 2003-12-03 | 全药工业株式会社 | 杂环化合物和以其为有效成分的抗肿瘤剂 |
| JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンａ３拮抗剤 |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| US6150362A (en) | 1997-12-12 | 2000-11-21 | Henkin; Jack | Triazine angiogenesis inhibitors |
| EP0930302B1 (en) | 1998-01-16 | 2003-04-02 | F.Hoffmann-La Roche Ag | Benzosulfone derivatives |
| WO1999065897A1 (en) | 1998-06-19 | 1999-12-23 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| CA2359680A1 (en) | 1999-01-22 | 2000-07-27 | David M. Armistead | Kinase inhibitors |
| US6495558B1 (en) | 1999-01-22 | 2002-12-17 | Amgen Inc. | Kinase inhibitors |
| EP1206260A4 (en) | 1999-06-30 | 2002-10-30 | Merck & Co Inc | SRC-KINASE INHIBITING COMPOUNDS |
| WO2001000213A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| EP1194152A4 (en) | 1999-06-30 | 2002-11-06 | Merck & Co Inc | Links to SRC kinase inhibition |
| AU777735B2 (en) | 1999-07-15 | 2004-10-28 | Pharmacopeia, Inc. | Bradykinin B1 receptor antagonists |
| JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
| AU3704101A (en) | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
| CN100355751C (zh) | 2000-03-29 | 2007-12-19 | 西克拉塞尔有限公司 | 2－取代的4－杂芳基－嘧啶、其组合物及其用途 |
| KR100774855B1 (ko) | 2000-04-27 | 2007-11-08 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 헤테로아릴 유도체 |
| CN1657523A (zh) | 2000-04-28 | 2005-08-24 | 田边制药株式会社 | 环状化合物 |
| WO2002000647A1 (en) | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| AU9502601A (en) | 2000-09-06 | 2002-03-22 | Chiron Corp | Inhibitors of glycogen synthase kinase 3 |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| SE0004053D0 (sv) | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
| US6989385B2 (en) | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002062766A2 (en) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| AU2002258400A1 (en) | 2001-02-16 | 2002-08-28 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| EP1395561A1 (en) | 2001-05-25 | 2004-03-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
| CA2450934A1 (en) | 2001-06-19 | 2002-12-27 | Marco Dodier | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| US6603000B2 (en) | 2001-07-11 | 2003-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis for heteroarylamine compounds |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| EP1485381B8 (en) | 2002-03-15 | 2010-05-12 | Vertex Pharmaceuticals Incorporated | Azolylaminoazine as inhibitors of protein kinases |
| US20040009981A1 (en) | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| US6846928B2 (en) | 2002-03-15 | 2005-01-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| DE60332433D1 (de) | 2002-03-15 | 2010-06-17 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
| US20040082627A1 (en) | 2002-06-21 | 2004-04-29 | Darrow James W. | Certain aromatic monocycles as kinase modulators |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| JP2006510597A (ja) | 2002-09-27 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 置換ピリミジン類 |
| US20040171073A1 (en) | 2002-10-08 | 2004-09-02 | Massachusetts Institute Of Technology | Compounds for modulation of cholesterol transport |
| US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
| EA013811B1 (ru) | 2002-11-21 | 2010-08-30 | Новартис Вэксинес Энд Дайэгностикс, Инк. | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака |
| JP2006521357A (ja) | 2003-03-24 | 2006-09-21 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物 |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| JP4895806B2 (ja) | 2003-04-09 | 2012-03-14 | エクセリクシス， インク． | Ｔｉｅ−２モジュレータと使用方法 |
| WO2005002514A2 (en) | 2003-06-13 | 2005-01-13 | Echelon Biosciences Incorporated | Compounds having inhibitibe activity of phosphatidylinositol 3-kinase and methods of use thereof |
| CA2531490A1 (en) | 2003-07-15 | 2005-02-03 | Neurogen Corporation | Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands |
| CA2531619A1 (en) | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| CA2561895A1 (en) | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
| GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| MY145822A (en) | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
| JP2008521900A (ja) | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
| WO2006065872A1 (en) | 2004-12-13 | 2006-06-22 | Neurogen Corporation | Piperazinyl-pyridine analogues |
| CA2590586A1 (en) | 2004-12-13 | 2006-07-06 | Neurogen Corporation | Substituted biaryl analogues |
| ES2382068T3 (es) | 2004-12-28 | 2012-06-05 | Kinex Pharmaceuticals, Llc | Composiciones y métodos para tratar trastornos de proliferación celular |
| WO2006078992A2 (en) | 2005-01-19 | 2006-07-27 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
| CA2599320A1 (en) | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents |
| TW200716594A (en) | 2005-04-18 | 2007-05-01 | Neurogen Corp | Substituted heteroaryl CB1 antagonists |
| US7930013B2 (en) | 2005-06-29 | 2011-04-19 | Compumedics Limited | Sensor assembly with conductive bridge |
| GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
| EP1979325A1 (en) | 2006-01-11 | 2008-10-15 | AstraZeneca AB | Morpholino pyrimidine derivatives and their use in therapy |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| EP2012794B1 (en) * | 2006-04-13 | 2014-09-17 | The Trustees of Columbia University in the City of New York | Compositions and intraluminal devices for inhibiting vascular stenosis |
| TW200833342A (en) | 2006-12-28 | 2008-08-16 | Basf Ag | 2-substituted pyrimidines I in therapy |
| WO2008098058A1 (en) | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
| US7957951B2 (en) | 2007-03-16 | 2011-06-07 | Robert Bosch Gmbh | Address translation system for use in a simulation environment |
| AU2008273889B2 (en) | 2007-07-09 | 2012-03-08 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| WO2009066084A1 (en) * | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
| US20110033453A1 (en) | 2008-03-05 | 2011-02-10 | Carlos Garcia-Echeverria | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| KR20100126553A (ko) | 2008-03-26 | 2010-12-01 | 노파르티스 아게 | Ｖｅｇｆ-유도성 혈관신생 과정의 유력한 조절제로서의 이미다조퀴놀린 및 피리미딘 유도체 |
| JP2011515462A (ja) | 2008-03-27 | 2011-05-19 | アウククランド ウニセルビセス リミテッド | 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用 |
| TW200948362A (en) | 2008-04-09 | 2009-12-01 | Mitsubishi Tanabe Pharma Corp | New compounds and their uses |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| WO2010049481A1 (en) | 2008-10-31 | 2010-05-06 | Novartis Ag | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| US8513242B2 (en) | 2008-12-12 | 2013-08-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| US8673891B2 (en) | 2009-02-06 | 2014-03-18 | Nippon Shinyaku Co., Ltd. | Aminopyrazine derivative and medicine |
| JP5747440B2 (ja) | 2009-02-06 | 2015-07-15 | 住友化学株式会社 | ヒドラジド化合物及びその有害生物防除用途 |
| US20120121515A1 (en) | 2009-03-13 | 2012-05-17 | Lenny Dang | Methods and compositions for cell-proliferation-related disorders |
| WO2010120994A2 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
| MX2011012343A (es) | 2009-05-19 | 2011-12-14 | Dow Agrosciences Llc | Compuestos y metodos para controlar hongos. |
| CA2767008C (en) | 2009-07-07 | 2018-01-30 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| WO2011017296A1 (en) | 2009-08-04 | 2011-02-10 | Schering Corporation | 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| JP2013504325A (ja) | 2009-09-09 | 2013-02-07 | アビラ セラピューティクス， インコーポレイテッド | Ｐｉ３キナーゼインヒビターおよびその使用 |
| ES2642109T3 (es) | 2009-12-09 | 2017-11-15 | Agios Pharmaceuticals, Inc. | Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH |
| GB201004200D0 (en) | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| WO2011143160A2 (en) | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| CN103097340B (zh) | 2010-07-16 | 2018-03-16 | 安吉奥斯医药品有限公司 | 治疗活性组合物及其使用方法 |
| SG188439A1 (en) | 2010-10-01 | 2013-05-31 | Novartis Ag | Manufacturing process for pyrimidine derivatives |
| SG189019A1 (en) | 2010-10-18 | 2013-05-31 | Cerenis Therapeutics Holding Sa | Compounds, compositions and methods useful for cholesterol mobilisation |
| GB201106829D0 (en) | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
| EP2673268A1 (en) | 2011-02-11 | 2013-12-18 | Dana-Farber Cancer Institute, Inc. | Method of inhibiting hamartoma tumor cells |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| WO2013030368A1 (en) | 2011-09-01 | 2013-03-07 | Novartis Ag | Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone |
| BR112014007310A2 (pt) | 2011-09-27 | 2017-04-04 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante |
| AU2012318874A1 (en) | 2011-10-06 | 2014-05-15 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine PDE10 inhibitors |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| WO2013173283A1 (en) | 2012-05-16 | 2013-11-21 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
| RU2014154009A (ru) | 2012-06-06 | 2016-08-10 | Новартис Аг | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания |
| WO2014028566A1 (en) | 2012-08-16 | 2014-02-20 | Novartis Ag | Combination of pi3k inhibitor and c-met inhibitor |
| AU2013336807B2 (en) | 2012-10-23 | 2016-10-27 | Novartis Ag | Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| JP6387360B2 (ja) | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン |
| CN103483345B (zh) | 2013-09-25 | 2016-07-06 | 中山大学 | Pi3k激酶抑制剂、包含其的药物组合物及其应用 |
| CN103694218B (zh) | 2013-12-05 | 2016-04-27 | 中山大学 | 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用 |
-
2013
- 2013-02-21 UY UY0001034632A patent/UY34632A/es not_active Application Discontinuation
- 2013-02-22 AR ARP130100536A patent/AR090121A1/es unknown
- 2013-02-22 AU AU2013223713A patent/AU2013223713C1/en active Active
- 2013-02-22 PE PE2014001291A patent/PE20142456A1/es not_active Application Discontinuation
- 2013-02-22 BR BR112014020672-4A patent/BR112014020672B1/pt active IP Right Grant
- 2013-02-22 NZ NZ629198A patent/NZ629198A/en not_active IP Right Cessation
- 2013-02-22 CA CA2865372A patent/CA2865372A1/en not_active Abandoned
- 2013-02-22 US US13/773,947 patent/US8865894B2/en active Active
- 2013-02-22 KR KR1020147023243A patent/KR101640698B1/ko active Active
- 2013-02-22 EP EP13717317.5A patent/EP2817307B1/en active Active
- 2013-02-22 EA EA201491579A patent/EA026031B1/ru not_active IP Right Cessation
- 2013-02-22 TW TW102106331A patent/TW201339155A/zh unknown
- 2013-02-22 MX MX2014010141A patent/MX353341B/es active IP Right Grant
- 2013-02-22 HK HK15100012.7A patent/HK1199643A1/xx unknown
- 2013-02-22 WO PCT/IB2013/051443 patent/WO2013124826A1/en not_active Ceased
- 2013-02-22 PT PT137173175T patent/PT2817307T/pt unknown
- 2013-02-22 SG SG11201404794XA patent/SG11201404794XA/en unknown
- 2013-02-22 AP AP2014007835A patent/AP2014007835A0/xx unknown
- 2013-02-22 ES ES13717317.5T patent/ES2598118T3/es active Active
- 2013-02-22 GE GEAP201313557A patent/GEP20156389B/en unknown
- 2013-02-22 CN CN201380010698.9A patent/CN104144926B/zh active Active
- 2013-02-22 PL PL13717317T patent/PL2817307T3/pl unknown
- 2013-02-22 JP JP2014558256A patent/JP6154404B2/ja active Active
-
2014
- 2014-07-23 ZA ZA2014/05446A patent/ZA201405446B/en unknown
- 2014-08-04 IL IL233936A patent/IL233936A/en not_active IP Right Cessation
- 2014-08-12 NI NI201400089A patent/NI201400089A/es unknown
- 2014-08-15 CO CO14179492A patent/CO7051028A2/es unknown
- 2014-08-22 PH PH12014501900A patent/PH12014501900A1/en unknown
- 2014-08-22 CR CR20140397A patent/CR20140397A/es unknown
- 2014-08-22 GT GT201400178A patent/GT201400178A/es unknown
- 2014-08-22 DO DO2014000194A patent/DOP2014000194A/es unknown
- 2014-09-05 US US14/478,523 patent/US9458177B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY34632A (es) | Compuestos de oxazolidin- 2- ona y usos de los mismos | |
| UY34781A (es) | Moduladores de la via del complemento y usos de los mismos | |
| UY34824A (es) | Nucleósidos de espirooxetano de uracilo | |
| UY34765A (es) | Compuestos novedosos. | |
| UY34797A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
| UY34763A (es) | Inhibidores de la agregación plaquetaria | |
| UY34536A (es) | Nucleósidos sustituidos, nucleótidos y análogos de los mismos | |
| UY34817A (es) | Tienopirimidinas | |
| UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| UY34778A (es) | ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA HETEROCÍCLICOS SUSTITUÍDOS?. | |
| UY34585A (es) | Compuestos b-lactámicos sustituidos con amidina, su preparación y uso | |
| UY34820A (es) | Compuestos tipo pirrolo-pirrolidinona | |
| UY34568A (es) | Imidazoles y pirazoles fusionados sustituidos y sus usos | |
| CR20150462A (es) | Inhibidores de erk y sus usos | |
| UY34539A (es) | Heteroarilos y usos de los mismos | |
| UY34605A (es) | Derivados de arilalquiloxipirimidina e insecticidas agrohortícolas que comprenden dichos derivados como principios activos, y método de uso de los mismos | |
| UY34484A (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| MX2015011514A (es) | Compuestos de heteroarilo y sus usos. | |
| CR20150524A (es) | Compuestos de heteroarilo y sus usos | |
| MX378288B (es) | Inhibidores de pirimidina del fgfr4. | |
| MX380146B (es) | Inhibidores mk2 y usos de los mismos. | |
| UY34472A (es) | Derivados modificados de 4-fenil-piridina | |
| UY34697A (es) | Métodos para preparar análogos de nucleótidos | |
| UY34418A (es) | Compuestos derivados de la piridopiracina, su preparación, composiciones que los contienen y su uso en terapia | |
| NI201400079A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20210526 |